T Cell-based Therapies

Traditionally, professional antigen-presenting cells (APCs) include dendritic cells (DCs), macrophages, and B cells. Though T cells are not considered primary APCs, they do have the capacity to serve as APCs in certain situations. Some studies reported that activated human T cells expressed MHC-II to present soluble antigens. The activated human γδ T cells also can serve as professional APCs.

At Creative Biolabs, we are dedicated to advancing the field of T-cell engineering through innovative research and development. We offer a range of T-cell engineering services, such as chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, γδ T-APC engineering, and T-cell gene editing. Scientists at our lab provide have expertise and technologies needed to develop these advanced therapies, supporting further advancements in the field of immunotherapy.

One-stop T Cell Engineering Services

Our T-cell engineering services include T-cell gene editing, CAR-T cell therapy, TCR-T cell therapy, and other services to improve T-cell function and increase their effectiveness in fighting diseases. At Creative Biolabs, we have developed a one-stop T-cell engineering platform for T-cell gene editing, cell culture, and functional testing of engineered T cells. Our team of experts has extensive experience in various gene delivery technologies, such as electroporation, viral transduction, and gene editing technologies. We are committed to customizing T-cell engineering solutions based on client's needs and supporting clients throughout the entire process, from initial consultation to the completion of their projects.

Our T Cell Platforms

Our scientists provide some common and novel T-cell engineering services including:

• γδ T-APC Engineering

Our expert team utilizes cutting-edge techniques and technologies to engineer γδ T cells for improved APC function. We aim at enhancing the ability of γδ T cells to efficiently present antigens to other immune cells and stimulate immune responses. These engineered γδ T-APCs have the potential to be used in cancer immunotherapy, infectious disease treatment, and other therapeutic approaches that require robust and targeted antigen presentation.

• CAR-T Cell Therapy

We are dedicated to advancing the field of CAR-T cell therapy and providing comprehensive support from initial consultation to CAR-T project development. Our team of experts assists with designing and constructing CAR vectors, optimizing T-cell transduction and expansion protocols, conducting in vitro and in vivo preclinical studies, and developing robust quality control assays to ensure the safety and efficacy of CAR-T cell therapies.

• TCR-T Cell Therapy

We offer comprehensive support and services for the development and manufacturing of TCR-engineered T cells. Our services include the design and optimization of TCR constructs, the generation and expansion of TCR-engineered T cells, and the characterization of these cells for potency and specificity.

In addition, we also provide other customized T-cell engineering services to improve T-cell function and safety.

• Knockout or Knockdown of Inhibitory Receptors

Modifying T cells to knock out or downregulate inhibitory receptors, such as PD-1 or CTLA-4, can improve T cell activation and function. Our experienced team provides customized genetic modification services to knock out or downregulate inhibitory receptors for enhancement of the efficacy of T-cell therapies.

• T Cell Modification with Cytokine Signaling

Our experts engineer T cells to express specific cytokines, chemokines, or their receptors, thus enhancing their proliferation, survival, and effector functions in the tumor microenvironment.

• T cell Modification with Suicide Genes

Incorporating suicide genes into T cells allows for their selective elimination in case of adverse events or uncontrolled proliferation, providing an added safety feature in gene-modified T cell therapies.

Contact Us

Our team of experts is equipped with advanced technologies and experience for modifying T cells, such as CAR-T cell therapy and TCR engineering. If you are seeking to advance the field of immunotherapy, our service can provide the support and expertise you need. Partner with us to access cutting-edge technologies, specialized expertise, and customized solutions to advance your T-cell therapy development program. Contact us today to learn more about how our T-cell engineering services can help you achieve your research goals.

Reference

1. Neal, Lillian R., et al. "The basics of artificial antigen-presenting cells in T cell-based cancer immunotherapies." Journal of immunology research and therapy 2.1 (2017): 68.

For Research Use Only | Not For Clinical Use